NeOnc Technologies (NTHI) vs Oncolytics Biotech (ONCY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Oncolytics Biotech (ONCY) has outperformed NeOnc Technologies (NTHI) over the past year, losing 55.1% versus a loss of 76.8%. NeOnc Technologies is the larger company by market cap ($80.1 million vs $73.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NTHI | ONCY |
|---|---|---|
| Share price | $2.78 | $0.557 |
| Market cap | $80.08M | $73.03M |
| 1-day change | +9.88% | +2.31% |
| YTD return | -66.38% | -35.98% |
| 1-year return | -76.79% | -55.08% |
| 5-year return | — | -74.91% |
| EPS (TTM) | $-2.13 | $-0.36 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.09 | $1.32 |
| 52-week low | $2.50 | $0.525 |
| Distance from 52-week high | -77.01% | -57.80% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +511.51% | +645.06% |
| Average volume | 195.17K | 1.08M |
| Shares outstanding | 28.81M | 131.12M |
| Employees | 5 | 29 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ONCY has outperformed NTHI by 21.7 percentage points over the past year.
About NeOnc Technologies
NTHI stock →NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
About Oncolytics Biotech
ONCY stock →Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal (GI) tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
NTHI vs ONCY FAQ
Which is bigger, NeOnc Technologies or Oncolytics Biotech?
NeOnc Technologies (NTHI) is larger, with a market capitalization of $80.08M compared with $73.03M for Oncolytics Biotech (ONCY).
Which stock has performed better over the past year, NTHI or ONCY?
ONCY returned -55.08% over the past 12 months, compared with -76.79% for NTHI (price return, excluding dividends). Past performance does not predict future results.
Are NeOnc Technologies and Oncolytics Biotech in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.